| abstract |
It is possible to apply the present invention to a mucous membrane capable of exhibiting a continuous therapeutic effect on diseases such as inflammation and damage in the mucosa even with a smaller administration frequency since the agent can exhibit a high retention characteristic in the epithelium of the mucosa and can stay in the lesion for a long period of time The above agent to be applied to the mucous membrane provides glycaminoglycan (GAG), into which a hydrophobic group is introduced via a bonding chain, as an active ingredient. |